Comparisons between differential NT-proBNP remission trajectories revealed that age, CTD duration, CTD immunotherapy, and PAH severity (6MWD, WHO-FC, RAD, RVDd, and pericardial effusion) significantly differed. This evidence concerns the gene NPPB and pericardial effusion.